Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Crunch time for multiple-gene tests

Sophisticated new genetic tests face an uncertain future — unless they can win clear-cut approval from regulators, insurers and, most importantly, doctors. Virginia Gewin reports.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Related links

Related links

Related links in Nature Research

Opinion: The US Food and Drug Administration perspective on cancer biomarker development

A regulatory perspective on in vitro diagnostics

New-wave diagnostics

Three barriers to innovative diagnostics

Related external links

FDA draft guidance on diagnostic assays

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Crunch time for multiple-gene tests. Nature 445, 354–355 (2007).

Download citation

  • Published:

  • Issue Date:

  • DOI:

This article is cited by


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing